Загрузка...
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma
Angiogenesis inhibitors targeting the VEGF signaling pathway have been US FDA approved for various cancers including glioblastoma (GBM), one of the most lethal and angiogenic tumors. This has led to the routine use of the anti-VEGF antibody bevacizumab in recurrent GBM, conveying substantial improve...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Future Medicine Ltd
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3673744/ https://ncbi.nlm.nih.gov/pubmed/23750318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.12.36 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|